Last quarter (Q4 2022), Pharma Mar SA's total revenue was $54.94M, a decrease of ― from the same quarter last year. In Q4, Pharma Mar SA's net income was $5.98M. See Pharma Mar SA’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 22	Dec 21	Dec 20	Dec 19	Dec 18
Total Revenue	$ 54.94M	$ 196.34M	$ ―	$ ―	$ 85.82M	$ 108.77M
Cost of Revenue	$ 6.23M	$ 13.64M	$ 76.74K	$ ―	$ 5.23M	$ 4.92M
Gross Profit	$ 48.71M	$ 182.70M	$ -76.74K	$ ―	$ 80.59M	$ 103.85M
Operating Expense	$ 45.54M	$ 138.27M	$ 759.43K	$ ―	$ 98.07M	$ 119.87M
Operating Income	$ 3.18M	$ 44.44M	$ -836.17K	$ ―	$ -17.48M	$ -16.03M
Net Non Operating Interest Income Expense	$ -7.41M	$ -1.50M	$ ―	$ ―	$ -3.85M	$ -4.11M
Other Income Expense	$ ―	$ ―	$ -1.49M	$ ―	$ ―	$ ―
Pretax Income	$ -2.82M	$ 43.79M	$ -2.32M	$ ―	$ -21.65M	$ -19.99M
Tax Provision	$ -4.21M	$ -5.57M	$ ―	$ ―	$ -12.47M	$ -2.88M
Earnings From Equity Interest Net Of Tax	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Net Income Common Stockholders	$ 5.98M	$ 49.36M	$ -2.32M	$ ―	$ -11.38M	$ -5.54M
Basic EPS	$ 0.33	$ 2.73	$ ―	$ ―	$ -0.60	$ -0.36
Diluted EPS	$ 0.33	$ 2.73	$ ―	$ ―	$ -0.60	$ -0.36
Basic Average Shares	$ 18.11M	$ 18.05M	$ ―	$ ―	$ 18.44M	$ 18.41M
Diluted Average Shares	$ 18.11M	$ 18.06M	$ ―	$ ―	$ 18.44M	$ 18.41M
Dividend Per Share	-	$ 0.65	$ ―	$ ―	$ ―	$ ―
Total Operating Income As Reported	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Reported Normalized Basic E P S	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Reported Normalized Diluted E P S	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Rent Expense Supplemental	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Total Expenses	$ 51.77M	$ 151.91M	$ -836.17K	$ ―	$ 103.29M	$ 124.80M
Net Income From Continuing And Discontinued Operation	$ 5.98M	$ 49.36M	$ -2.32M	$ ―	$ -11.38M	$ -5.54M
Normalized Income	$ 169.51K	$ 50.71M	$ -2.32M	$ ―	$ -8.96M	$ -17.15M
Interest Expense	$ ―	$ 2.38M	$ ―	$ ―	$ 3.89M	$ 4.14M
EBIT	$ 2.67M	$ 46.17M	$ -2.32M	$ ―	$ -17.77M	$ -15.85M
EBITDA	$ 6.97M	$ 52.07M	$ ―	$ ―	$ -9.73M	$ -9.47M

Currency in USD

Pharma Mar SA Earnings and Revenue History

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing